Equitec Proprietary Markets, LLC Lava Therapeutics Nv Transaction History
Equitec Proprietary Markets, LLC
- $415 Million
- Q3 2025
A detailed history of Equitec Proprietary Markets, LLC transactions in Lava Therapeutics Nv stock. As of the latest transaction made, Equitec Proprietary Markets, LLC holds 15,400 shares of LVTX stock, worth $25,564. This represents 0.01% of its overall portfolio holdings.
Number of Shares
15,400Holding current value
$25,564% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding LVTX
# of Institutions
27Shares Held
7.26MCall Options Held
131KPut Options Held
51.8K-
Shay Capital LLC New York, NY2.55MShares$4.23 Million0.44% of portfolio
-
Redmile Group, LLC San Francisco, CA2.07MShares$3.44 Million0.36% of portfolio
-
Bml Capital Management, LLC Zionsville, IN1.97MShares$3.27 Million2.81% of portfolio
-
Gts Securities LLC New York, NY200KShares$332,0000.01% of portfolio
-
Rangeley Capital, LLC New Canaan, CT165KShares$273,9000.22% of portfolio
About LAVA Therapeutics NV
- Ticker LVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,797,700
- Market Cap $42.8M
- Description
- LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer...